| Abstrakt: |
In 2022, we conducted a survey to assess how institutions were handling regenerative medical products. The survey was distributed to 203 facilities, including university hospitals, national and public hospitals, Japan Marrow Donor Program-certified hospitals, children's hospitals, and perinatal medical centers. A total of 140 facilities responded. The current status of in-hospital adoption of regenerative medical products is as follows: among 11 types of human cell/tissue products, Temcell® HS had the high usage rate of 80.7%, while Kymriah® (Tisagenlecleucel) had a usage rate of 28.6%. Of the three types of gene therapy product, Zolgensma® (Onasemnogene abeparvovec-xioi) had the highest usage rate at 18.6%. Regarding transfusion departments, while these were involved in the apheresis and management of regenerative medical products, they had was no involvement with Nepic® or Ocural®. It should be noted that these products are specified as designated-regenerative medical products, and the storage of administration records within the institution is therefore mandated, similarly as for blood products. Some of these products involve the participation of specialized departments, but the majority were under management of the respective medical department and pharmacy division. This survey highlighted challenges in the management and handling of regenerative medical products within the hospital from the perspective of the transfusion department. [ABSTRACT FROM AUTHOR] |
